Maintenance therapy with the drug lenalidomide (Revlimid) substantially lengthens the time patients with multiple myeloma live without their cancers progressing, according to the results of three randomized placebo-controlled clinical trials published May 10 in the New England Journal of Medicine. Overall survival was also improved in one of the trials, but according to several researchers, that conclusion is less definitive.
The results also showed that lenalidomide maintenance therapy carries an increased risk of second primary cancers. Read more > >
A MESSAGE TO READERS
Coverage of ASCO Annual Meeting
The American Society of Clinical Oncology's 48th Annual Meeting will take place June 1–5 in Chicago, IL. Click on the tile to learn more about sessions with NCI staff and activities at the NCI exhibit booth. Look for highlights from the meeting in the May 29 and June 12 issues of the NCI Cancer Bulletin.
Selected articles from past issues of the NCI Cancer Bulletin are available in Spanish.
The NCI Cancer Bulletin is produced by the National Cancer Institute (NCI), which was established in 1937. Through basic, clinical, and population-based biomedical research and training, NCI conducts and supports research that will lead to a future in which we can identify the environmental and genetic causes of cancer, prevent cancer before it starts, identify cancers that do develop at the earliest stage, eliminate cancers through innovative treatment interventions, and biologically control those cancers that we cannot eliminate so they become manageable, chronic diseases.
For more information about cancer, call 1-800-4-CANCER or visit http://www.cancer.gov.
NCI Cancer Bulletin staff can be reached at email@example.com.